Uveitis Trial, Recruiting NCT05590416 Sponsor: Tianjin Medical University Condition: Uveitis
Back to Uveitis

Uveitis Trial, Recruiting

NCT05590416
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 70 years old
  • You have never had tuberculosis (TB) in the past, and do not currently have an active or dormant TB infection
  • You have been diagnosed with Vogt-Koyanagi-Harada (VKH) disease for less than one month
  • You have been treated with steroid tablets or injections (taken throughout the body, not just the eye) for less than one week
  • You meet at least one of the following: you do not want to take long-term steroids because of the side effects; you have another health condition that makes taking steroids risky or unsuitable; or your retinal detachment has not improved much after one week of high-dose steroid treatment

Who may not be able to join:

  • You have, or are suspected to have, an eye inflammation caused by an infection (such as TB, herpes, toxoplasmosis, Lyme disease, or several other infections)
  • You have cloudiness in the cornea or lens of your eye that blocks a clear view of the back of your eye, or that is likely to need cataract surgery during the trial
  • You have previously been treated with a type of medication called anti-TNF therapy or any similar biological drug used to treat eye inflammation
  • You have received a specific steroid eye implant called Ozurdex® within the last 6 months
  • You have received certain injections into the eye (anti-VEGF treatments such as Lucentis®, Avastin®, or Eylea®) within the last 45 to 60 days, depending on the specific medication
  • You have received methotrexate injected into the eye within the last 90 days

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +86-13920023990

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Tianjin Medical University
Registry
ClinicalTrials.gov
Start date
1 June 2021
Est. completion
1 December 2024

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change In LogMAR Best Corrected Visual Acuity (BCVA) From Baseline to Each Visit.; Recurrence rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov